Department of Medicine/Cardiology, Caritas St Elizabeth Medical Center, Tufts School of Medicine, Boston, Massachusetts 02135, USA.
J Cardiovasc Med (Hagerstown). 2010 Feb;11(2):103-10. doi: 10.2459/JCM.0b013e32832ffc85.
Percutaneous intervention of true coronary bifurcation lesions is challenging. Based on the results of randomized trials and registry data, the approach of stenting of main vessel only with balloon dilatation of the side branch has become the default approach for false bifurcation lesions except when a complication occurs or in cases of suboptimal result. However, the optimal stenting strategy for true coronary bifurcation lesions - to stent or not to stent the side branch - is still a matter of debate. The purpose of this study was, therefore, to compare the clinical and angiographic outcomes of the double stent technique (stenting of the main branch and side branch) over the single stent technique (stenting of main vessel only with balloon dilatation of the side branch) for treatment of true coronary bifurcation lesions, with drug-eluting stents (DES).
Comparative studies published between January 2000 and February 2009 of the double stent technique vs. single stent technique with DES for true coronary bifurcations were identified using an electronic search and reviewed using a random effects model. The primary endpoints of our study were side-branch and main-branch restenoses, all-cause mortality, myocardial infarction (MI) and target lesion revascularization (TLR) at longest available follow-up. The secondary endpoints of our analysis were postprocedural minimal luminal diameter (MLD) of the side branch and main branch, follow-up MLD of side branch and main branch and stent thrombosis. Heterogeneity was assessed and sensitivity analysis was performed to test the robustness of the overall summary odds ratios (ORs).
Five studies comprising 1145 patients (616 single stent and 529 double stent) were included in the analysis. Three studies were randomized comparisons between the two techniques for true coronary bifurcation lesions. Incomplete reporting of data in the primary studies was common. The lengths of clinical and angiographic follow-up ranged between 6 and 12 months and 6 and 7 months, respectively. Postprocedural MLD of the side branch was significantly smaller in the single stent group [standardized mean difference (SMD) -0.71, 95% CI -0.88 to -0.54, P < 0.000, I2 = 0%]. The odds of side-branch restenosis (OR 1.11, 95% CI 0.47-2.67, P = 0.81, I2 = 76%), main-branch restenois (OR 0.88, 95% CI 0.56-1.39, P = 0.58, I = 0%), all-cause mortality (OR 0.52, 95% CI 0.11-2.45, P = 0.41, I2 = 0%), MI (OR 0.92, 95% CI 0.34-2.54, P = 0.87, I = 49%) and TLR (OR 0.87, 95% CI 0.46-1.65, P = 0.68, I2 = 0%) were similar between the two groups. Postprocedural MLD of the main branch [standardized mean difference (SMD) -0.08, 95% CI -0.42 to -0.26, P < 0.65, I2 = 67%], follow-up MLD of side branch (SMD -0.19, 95% CI -0.40 to 0.01, P < 0.31, I2 = 15%) and main branch MLD (SMD 0.17, 95% CI -0.18 to 0.542, P < 0.35, I2 = 65%) were also similar between the two groups.
In patients undergoing percutaneous coronary intervention (PCI) for true coronary bifurcations, there is no added advantage of stenting both branches as compared with a conventional one-stent strategy. The results, however, need to be interpreted considering the poor study methods and/or poor quality of reporting in publications. We propose to move forward and consider the conduct of more systematic, well-designed and scientific trials to investigate the treatment of true coronary bifurcation lesions.
经皮冠状动脉介入治疗真性冠状动脉分叉病变具有挑战性。基于随机试验和注册数据的结果,除发生并发症或结果不理想外,主血管支架置入术联合分支球囊扩张已成为真性冠状动脉分叉病变的默认治疗方法。然而,对于真性冠状动脉分叉病变的最佳支架置入策略(是否置入分支支架)仍存在争议。本研究的目的是比较双支架技术(主支和分支支架置入)与单支架技术(主支支架置入联合分支球囊扩张)在药物洗脱支架(DES)治疗真性冠状动脉分叉病变中的临床和血管造影结果。
通过电子检索,确定了 2000 年 1 月至 2009 年 2 月期间比较双支架技术与单支架技术治疗真性冠状动脉分叉病变的研究,并使用随机效应模型进行了回顾分析。本研究的主要终点是分支和主支再狭窄、全因死亡率、心肌梗死(MI)和靶病变血运重建(TLR),最长随访时间可用。我们分析的次要终点是分支和主支的术后最小管腔直径(MLD)、分支和主支的随访 MLD 以及支架血栓形成。评估了异质性,并进行了敏感性分析,以检验总体汇总优势比(OR)的稳健性。
共纳入 1145 例患者(616 例单支架组和 529 例双支架组)的 5 项研究。其中 3 项研究为真性冠状动脉分叉病变两种技术的随机比较。原始研究中数据报告不完整较为常见。临床和血管造影随访时间分别为 6 至 12 个月和 6 至 7 个月。单支架组术后分支 MLD 明显较小[标准化均数差值(SMD)-0.71,95%可信区间(CI)-0.88 至-0.54,P < 0.000,I² = 0%]。分支再狭窄(OR 1.11,95%CI 0.47-2.67,P = 0.81,I² = 76%)、主支再狭窄(OR 0.88,95%CI 0.56-1.39,P = 0.58,I = 0%)、全因死亡率(OR 0.52,95%CI 0.11-2.45,P = 0.41,I² = 0%)、心肌梗死(OR 0.92,95%CI 0.34-2.54,P = 0.87,I = 49%)和 TLR(OR 0.87,95%CI 0.46-1.65,P = 0.68,I² = 0%)的发生在两组之间相似。术后主支 MLD[SMD-0.08,95%CI-0.42 至-0.26,P < 0.65,I² = 67%]、分支随访 MLD[SMD-0.19,95%CI-0.40 至 0.01,P < 0.31,I² = 15%]和主支 MLD[SMD 0.17,95%CI-0.18 至 0.542,P < 0.35,I² = 65%]也在两组之间相似。
在接受经皮冠状动脉介入治疗(PCI)治疗的真性冠状动脉分叉病变患者中,与常规单支架策略相比,支架置入两支血管并没有额外的优势。然而,考虑到研究方法和/或出版物中报告质量较差,结果需要进行解释。我们建议继续进行更系统、精心设计和科学的试验,以研究真性冠状动脉分叉病变的治疗方法。